retatrutide mechanism gip glp-1 glucagon triple agonist Schematic illustration of monoagonists, dual agonists and A review of an investigational

65 Specifically, it has been documented to improve vascular function, glucose/lipid metabolism, oxidative stress, inflammation (IL-6 & TNF-alpha), and lipogenesis [82]

10.1053/j.gastro.2007.03.054 10 BarreraJ

62 Table 4

Results: GLP-1RA therapy was associated with lower risks of aortic rupture/dissection requiring surgical repair (hazard ratio [HR] 0.75, 95% CI 0.60 0.94

To help visualise the expected weight loss at different doses, let's look at this comparative table: These percentages represent average weight loss from baseline over a 68-72 week period, based on the SURMOUNT-1 trial for Mounjaro and the STEP-1 trial for Wegovy